Assessment of myocardial ischaemia and viability: Role of positron emission tomography

European Heart Journal

Volumn 31, Issue 24, 2010, Pages 2984-2995

  Ghosh, Nina ^a   Rimoldi, Ornella E ^b,c   Beanlands, Rob S B ^a   Camici, Paolo G ^c,d  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Myocardial ischaemia; PET

Indexed keywords

ACETIC ACID C 11; AMMONIA N 13; FLUORO 4 THIA PALMITIC ACID F 18; FLUORO 6 THIA HEPTADECANOIC ACID F 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE C 11; OXYGEN 15; PALMITIC ACID C 11; RUBIDIUM 82; STRONTIUM 82; TRACER; UNCLASSIFIED DRUG; WATER O 15;

CLINICAL ASSESSMENT; CORONARY FLOW RESERVE; ENERGY METABOLISM; GLUCOSE CLAMP TECHNIQUE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MYOCARDIAL HIBERNATION; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRESS ECHOCARDIOGRAPHY; STUNNED HEART MUSCLE; SURVIVAL;

FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL REVASCULARIZATION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 78650340295     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq361     Document Type: Review

References (98)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
2. US Food & Drug Administration. Technetium-99m radiopharmaceutical product shortage. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders/ucm176226.htm (6 July 2010).
3. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J Nucl Med 2009;50:1076-1087.
4. Dobrucki LW, Sinusas AJ. PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol 2010;7:38-47.
5. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994; 35(4 Suppl.):8S-14S.
6. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol 2009;54:1-15.
7. Knuuti J, Schelbert HR, Bax JJ. The need for standardisation of cardiac FDG PET imaging in the evaluation of myocardial viability in patients with chronic ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 2002;29:1257-1266.
8. Krivokapich J, Smith GT, Sung-Cheung H, Hoffman EJ, Osman R, Phelps ME, Schelbert HR. 13-N ammonia myocardial imaging at rest and with exercise in normal volunteers; Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 1989;80:1328-1337.
9. Araujo LI, Lammertsma AA, Rhodes CG, McFalls EO, Iida H, Rechavia E, Galassi A, De Silva R, Jones T, Maseri A. Noninvasive quantification of regional myocardial blood flow in normal volunteers and patients with coronary artery disease using oxygen-15 labeled water and positron emission tomography. Circulation 1991;83:875-885.
10. Bassingthwaighte JB, Beard DA. Fractal 15O-labeled water washout from the heart. Circ Res 1995;77:1212-1221.
11. Rimoldi O, Schafers KP, Boellaard R, Turkheimer F, Stegger L, Law MP, Lammerstma AA, Camici PG. Quantification of subendocardial and subepicardial blood flow using 15O-labeled water and PET: experimental validation. J Nucl Med 2006;47:163-172.
12. Di Carli MF, Dorbala S. Cardiac PET-CT. J Thorac Imaging 2007;22:101-106.
13. Souvatzoglou M, Bengel F, Busch R, Kruschke C, Fernolendt H, Lee D, Schwaiger M, Nekolla SG. Attenuation correction in cardiac PET/CT with three different CT protocols: a comparison with conventional PET. Eur J Nucl Med Mol Imaging 2007;34:1991-2000.
14. Lubberink M, Harms HJ, Halbmeijer R, de Haan S, Knaapen P, Lammertsma AA. Low-dose quantitative myocardial blood flow imaging using 15O-water and PET without attenuation correction. J Nucl Med 2010;51:575-580.
15. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Gropler RJ, Knuuti J, Schelbert HR, Travin MI. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 2009;16:651.
16. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, Hertenstein GK, Moutray KL, Reid K, Cullom SJ. Diagnostic accuracy of rest/ stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:24-33.
17. Lalonde L, Ziadi MC, Beanlands R. Cardiac positron emission tomography: current clinical practice. Cardiol Clin 2009;27:237-255.
18. Ziadi MC, deKemp R, Yoshinaga K, Beanlands R. Myocardial perfusion and flow with PET. In: Zaret B, Beller G, eds. Clinical Nuclear Cardiology: State of the Art and Future Directions. 4th ed. Philadelphia: Mosby Elsevier; 2010.
19. Go RT, Marwick TH, MacIntyre WJ, Saha GB, Neumann DR, Underwood DA, Simpfendorfer CC. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 1990;31:1899-1905.
20. Stewart R, Schwaiger M, Molina M, Popma J, Gacioch G, Kalus M, Squicciarini S, Al-Aouar Z, Schork A, Kuhl D. Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol 1991;67:1303-1310.
21. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol 1997;80:865-870.
22. Yoshinaga K, Chow BJ, Williams K, Chen L, deKemp RA, Garrard L, Lok-Tin SA, Aung M, Davies RA, Ruddy TD, Beanlands RS. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006;48:1029-1039.
23. Dorbala S, Hachamovitch R, Curillova Z, Thomas D, Vangala D, Kwong RY, Di Carli MF. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc Imaging 2009;2:846-854.
24. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, Heller GV. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 2008;15:745-753.
25. Uren NG, Melin JA, De Bruyne B, Wijins W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary artery stenosis. N Engl J Med 1994;330:1782-1788.
26. Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, Phelps ME, Schelbert HR. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 1995;91:1944-1951.
27. Choudhury L, Rosen SD, Patel D, Nihoyannopoulos P, Camici PG. Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy. A study with positron emission tomography. Eur Heart J 1997;18:108-116.
28. Sdringola A, Dhaval P, Gould KL. High prevalence of myocardial perfusioin abnormalities on positron emission tomography in asymptomatic persons with a parent or sibling with coronary artery disease. Circulation 2001;103:496-501.
29. Rajappan K, Rimoldi O, Dutka D, Ariff B, Pennell D, Sheridan D, Camici P. Mechanism of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002;105:470-476.
30. Radvan J, Choudhury L, Sheridan DJ, Camici PG. Comparison of coronary vasodilator reserve in elite rowing athletes versus hypertrophic cardiomyopathy. Am J Cardiol 1997;80:1621-1623.
31. Rosen S, Uren NG, Kaski J-C, Tousoulis D, Davies G, Camici P. Coronary vasodilator reserve, pain perception, and sex in patients with syndrome X. Circulation 1994;90:50-60.
32. Chareonthaitawee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res 2001;50:151-161.
33. Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege HL, Zeebregts CJ, Dierckx RA, van Veldhuisen DJ, Zijlstra F, Slart RH. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med 2009;50:214-219.
34. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA. Long-term prognostic value of 13N-ammonia myocar-dial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009;54:150-156.
35. Ziadi MC, Beanlands R, DeKemp R, Renaud J, RE T, Guo A, Williams K, Chow B, Ruddy TD, Hessian R, Garrard L, Davies RA, Etele J. Impaired MFR measured using Rb-82 predicts outcomes in patients with suspected ischemia. Circulation 2009;120:S320.
36. Ziadi MC, Garrard L, Beanlands R, DeKemp R, Guo A, Williams K, Chow B, Ruddy TD, Renaud J, Hessian R, Davies RA, Etele J. Reduced MFR quantified Rb-82 is an independent prediction of 3-V CAD. Circulation 2009;120:S320-S321.
37. Madar I, Ravert H, Dipaula A, Du Y, Dannals RF, Becker L. Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: comparison with 99mTc-tetrofosmin. J Nucl Med 2007;48:1021-1030.
38. Yu M, Guaraldi MT, Mistry M, Kagan M, McDonald JL, Drew K, Radeke H, Azure M, Purohit A, Casebier DS, Robinson SP. BMS-747158-02: a novel PET myocardial perfusion imaging agent. J Nucl Cardiol 2007;14:789-798.
39. Maddahi J, Schiepers C, Czernin J, Sparks R, Phelps M. First human study of BMS747158, a novel F-18 labeled tracer for myocardial perfusion imaging. J Nucl Med 2008;49:70P.
40. Tennant R, Wiggers C. Effect of coronary occlusion on myocardial contraction. Am J Physiol 1935;112:351-361.
41. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myo-cardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975;56:978-985.
42. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149.
43. Ambrosio G, Betocchi S, Pace L, Losi MA, Perrone-Filardi P, Soricelli A, Piscione F, Taube J, Squame F, Salvatore M, Weiss JL, Chiariello M. Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease. Circulation 1996; 94:2455-2464.
44. Barnes E, Hall RJ, Dutka DP, Camici PG. Absolute blood flow and oxygen consumption in stunned myocardium in patients with coronary artery disease. J Am Coll Cardiol 2002;39:420-427.
45. Diamond GA, Forrester JS, deLuz PL, Wyatt HL, Swan HJ. Post-extrasystolic potentiation of ischemic myocardium by atrial stimulation. Am Heart J 1978;95: 204-209.
46. Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985;72: V123-V135.
47. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008;117:103-114.
48. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007;32: 375-410.
49. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339: 173-181.
50. Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Program of cell survival underlying human and experimental hibernating myocardium. Circ Res 2004;95: 433-440.
51. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-888.
52. Beanlands R, Ruddy T, de Kemp R, Iwanochko RM, Coates G, Freeman M, Nahmais C, Hendry P, Burns RJ, Lamy A, Mickleborough L, Kostuk W, Fallen E, Nichol G, PARR Investigators. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002;40:1735-1743.
53. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, Gulenchyn KY, Garrard L, de Kemp R, Guo A, Ruddy TD, Benard F, Lamy A, Iwanochko RM. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002-2012.
54. Bax JJ, Patton JA, Poldermans D, Elhendy A, Sandler MP. 18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography: cardiac applications. Semin Nucl Med 2000;30:281-298.
55. Fallavollita JA, Luisi AJ Jr., Yun E, Dekemp RA, Canty JM Jr. An abbreviated hyperinsulinemic-euglycemic clamp results in similar myocardial glucose utilization in both diabetic and non-diabetic patients with ischemic cardiomyopathy. J Nucl Cardiol 2010;17:637-645.
56. Sun KT, Yeatman L, Buxton D, Chen K, Johnson JA, Huang S-C, Kofoed KF, Weismueller S, Czernin J, Phelps ME, Schelbert HR. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-Carbon-11] acetate. J Nucl Med 1998;39:272-280.
57. Gropler R, Shelton ME, Herrero P, Walsh JF, Bergmann SR. Measurement of myo-cardial oxygen consumption using positron emission tomography and C-11 acetate: direct validation in human subjects. Circulation 1993;88:I-172.
58. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996-1002.
59. Beanlands RS, Chow BJ, Dick A, Friedrich MG, Gulenchyn KY, Kiess M, Leong-Poi H, Miller RM, Nichol G, Freeman M, Bogaty P, Honos G, Hudon G, Wisenberg G, Van Berkom J, Williams K, Yoshinaga K, Graham J. CCS/CAR/ CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease-executive summary. Can J Cardiol 2007;23:107-119.
60. Beanlands R, Thorn S, DaSilva J, Ruddy T, Maddahi J. Myocardial viability. In: Wahl R, ed. Principles and Practices of Positron Emission Tomography. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2008.
61. Dokainish H, Freidrich M, Ziadi MC, Beanlands R. Imaging in the patient with heart failure. In: Mann D, ed. Heart Failure: A Companion to Braunwald's Heart Disease. Philadelphia: Elsevier; 2010 (in press).
62. Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, Konishi Y, Hirata K, Ban T, Konishi J. Positron emission tomography using fluorine-18-deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-865.
63. Vitale G, de Kemp R, Ruddy TD, Beanlands R. Myocardial glucose utilization and the optimization of F-18-FDG PET imaging in patients with NIDDM, CAD and LV dysfunction. J Nucl Med 2001;42:1730-1736.
64. vom Dahl J, Eitzman DT, Al-Aouar ZR, Kanter HL, Hicks RJ, Deeb GM, Kirsch MM, Schwaiger M. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascular-ization. Circulation 1994;90:2356-2365.
65. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czernin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Schelbert HR, Phelps ME, Maddahi J. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-533.
66. D'Egidio G, Nichol G, Williams K, Guo A, Garrard L, de Kemp R, Ruddy T, DaSilva J, Humen D, Gulenchyn K, Freeman M, Racine N, Benard F, Hendry P, Beanlands R. Identification of high-risk patients with increasing ischemic cardio-myopathy. JACC Cardiovasc Imaging 2009;2:1060-1068.
67. Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol 2010;17:646-654.
68. Medical Advisory Secretariat. Positron emission tomography (PET) for the assessment of myocardial viability: an evidence-based analysis. http://www.health.gov.on. ca/english/providers/program/ohtac/tech/draft-comment/ rev-cardiacmyo-pet- 20100429.pdf (6 July 2010).
69. Thompson K, Saab G, Birnie D, Chow BJ, Ukkonen H, Ananthasubramaniam K, Dekemp RA, Garrard L, Ruddy TD, Dasilva JN, Beanlands RS. Is septal glucose metabolism altered in patients with left bundle branch block and ischemic cardi-omyopathy? J Nucl Med 2006;47:1763-1768.
70. Inoue N, Takahashi N, Ishikawa T, Sumita S, Kobayashi T, Matsushita K, Matsumoto K, Taima M, Shimura M, Uchino K, Kimura K, Inoue T, Umemura S. Reverse perfusion-metabolism mismatch predicts good prognosis in patients undergoing cardiac resynchronization therapy: a pilot study. Circ J 2007;71: 126-131.
71. Birnie D, DeKemp RA, Ruddy TD, Tang AS, Guo A, Williams K, Wassenar R, Lalonde M, Beanlands RS. Effect of lateral wall scar on reverse remodeling with cardiac resynchronization therapy. Heart Rhythm 2009;6:1721-1726.
72. Ypenburg C, Schalij MJ, Bleeker GB, Steendijk P, Boersma E, Dibbets-Schneider P, Stokkel MP, van der Wall EE, Bax JJ. Extent of viability to predict response to cardiac resynchronization therapy in ischemic heart failure patients. J Nucl Med 2006;47:1565-1570.
73. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;273:E214-E223.
74. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, Ferrannini E. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996;98:2094-2099.
75. Marinho NVS, Keogh BE, Costa DC, Lannerstma AA, Ell PJ, Camici PG. Pathophy-siology of chronic left ventricular dysfunction: new insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation 1996;93: 737-744.
76. Fath-Ordoubadi F, Beatt KJ, Spyrou N, Camici PG. Efficacy of coronary angio-plasty for the treatment of hibernating myocardium. Heart 1999;82:210-216.
77. Lautamaki R, Airaksinen KE, Seppanen M, Toikka J, Luotolahti M, Ball E, Borra R, Harkonen R, Iozzo P, Stewart M, Knuuti J, Nuutila P. Rosiglitazone improves myo-cardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 2005;54:2787-2794.
78. Knuuti MJ, Saraste M, Nuutila P, Härkönen R, Wegelius U, Haapanen A, Bergman J, Haaparanta M, Savunen T, Voipio-Pulkki LM. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127:785-796.
79. Marwick T, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation 1992;85:1347-1353.
80. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Irwan R, Sluiter WJ, Dierckx RA, de Boer J, Jager PL. Prediction of functional recovery after revascu-larization in patients with chronic ischaemic left ventricular dysfunction: head-to-head comparison between 99mTc-sestamibi/18F-FDG DISA SPECT and 13N-ammonia/18F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:716-723.
81. Slart RH, Bax JJ, van Veldhuisen DJ, van der Wall EE, Dierckx RA, de Boer J, Jager PL. Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. J Nucl Cardiol 2006;13:210-219.
82. Siebelink H-M, Blanksma PK, Crijns H, Bax JJ, Van Boven AJ, Kingma T, Piers D, Pruim J, Jager P, Vaalburg W, van der Wall EE. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided management. J Am Coll Cardiol 2001;37:81-88.
83. Eitzman D, Al-Aouar Z, Kanter HL, vom Dahl J, Kirsch M, Deeb GM, Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-565.
84. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK, MacIntyre WJ, Thomas JD. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: Relative efficacy of medical therapy and revascularization. Circulation 1995;90:2687-2694.
85. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction:a meta-analysis.J Am Coll Cardiol 2002;39:1151-1158.
86. Desideri A, Cortigiani L, Christen AI, Coscarelli S, Gregori D, Zanco P, Komorovsky R, Bax JJ. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2005;46:1264-1269.
87. Pitt M, Dutka D, Pagano D, Camici P, Bonser R. The natural history of myocardium awaiting revascularisation in patients with impaired left ventricular function. Eur Heart J 2004;25:500-507.
88. Beanlands RS, Hendry P, Masters R, de Kemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe LV dysfunction and viable myocardium on fluorine-18- fluorodeoxyglucose positron emission tomography imaging. Circulation 1998;98:II-51-II-56.
89. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK, MacIntyre WJ, Thomas JD. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994;90:2687-2694.
90. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch-Herold M, Brown KA, Kwong RY. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009;120: 1390-1400.
91. McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med 2010;362: 228-238.
92. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De Caterina R, Dean V, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-2442.
93. Velazquez EJ, Lee KL, O'Connor CM, Oh JK, Bonow RO, Pohost GM, Feldman AM, Mark DB, Panza JA, Sopko G, Rouleau JL, Jones RH. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 2007;134:1540-1547.
94. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009;360:1705-1717.
95. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009;360:961-972.
96. Pagano D, Fath-Ordoubadi F, Beatt KJ, Townend JN, Bonser RS, Camici PG. Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium. Heart 2001;85:208-212.
97. Camici PG, Dutka DP. Repetitive stunning, hibernation, and heart failure: contribution of PET to establishing a link. Am J Physiol Heart Circ Physiol 2001;280: H929-H936.
98. Gropler RJ, Beanlands RS, Dilsizian V, Lewandowski ED, Villanueva FS, Ziadi MC. Imaging myocardial metabolic remodeling. J Nucl Med 2010;51:1S-14.